Displaying 259 - 264 of 510 News articles. Show 5 | 10 | 20 | 40 | 60 results per page.
Read the latest news from PraxisAuril on the world of Knowledge ExchangeSunderland University to support the city’s entrepreneurial growth
10 Apr 2017
Hope Street Xchange is a £10m centre for enterprise and innovation, funded by the University of Sunderland and supported by £4.9m investment from the North East Local Enterprise Partnership’s Local Growth Fund. The centre has been designed to support the city’s entrepreneurial growth.
PraxisUnico and AURIL form a single organisation to represent KEC professionals in the UK
7 Apr 2017
The Directors of PraxisUnico and AURIL are delighted to announce that they have formally agreed to join forces to form one organisation representing the Knowledge Exchange and Commercialisation (KEC) profession in the UK, effective 1 April 2017.
Oxford University Spinout’s vison of next-generation vaccines.
3 Apr 2017
SpyBiotech, an Oxford University spinout, has established a molecular superglue that can facilitate rapid development of robust and novel vaccines. The spinout has secured £4m seed funding from Oxford Sciences Innovation with participations from GV (formerly Google Ventures).
New Issue of KEC Matters: April 2017
3 Apr 2017
The new issue of KEC Matters is now available to download. This issue features articles on:
Is innovation a teachable skill?
27 Mar 2017
Dr Charles Brauer, director of innovation at Goldsmiths, University of London, argues that innovation is a teachable skill; innovation and new products are not a result of random inspiration and innate creativity. Teaching the skill of innovation means tapping into real-world problems with an evidence-based toolkit, rather than just relying on lightbulb moments.
New Era in Precision Medicine for Pancreatic Cancer
24 Mar 2017
Cancer Research UK invested £10 million for the development of new treatments for pancreatic cancer. They announced today that the treatments are set to be transformed by a network of clinical trials aiming to find the right trial for the right patient.